In addition to reducing symptoms of depression, the psychedelic drug 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) appears to cause changes in inflammatory biomarkers, according to preliminary research published in the journal Psychopharmacology.

“5-MeO-DMT is a very unique and interesting molecule which certainly deserves further scientific attention,” said study author Malin Uthaug (@malin.uthaug), a PhD candidate at Maastricht University in the Netherlands.

“As it is a rather unexplored area, I’ve been researching the effects of the fast-acting psychedelic substance for the past 2-3 years as part of my doctoral work at Maastricht University. This study is the second published study on the topic from my dissertation, which I will defend during the spring 2020.”

Continue reading on Psypost.org